1.Application of CD-DST in Treatment of Carcinoma of Large Intestine
Journal of Zhejiang Chinese Medical University 2006;0(02):-
It makes review on the application of CD-DST on clinical treatment and sci-research of the carcinoma of large intestine from its technological principle and characteristics.It views that as an advanced test technology of medical allergy in vitro, there’s successful report in clinical treatment and concerned scientific study of tumor, however, it’s mainly used in lung cancer and gynecological tumor, the application in the carcinoma of large intestine waits for promotion.
2.Effect of Fengbei Huayu Capsule on FasL Gene Expression and T Cell Apoptosis of Type 2 Diabetic Rats
Haimin GONG ; Wenzhuo DUAN ; Guangxiang JIN
Chinese Journal of Information on Traditional Chinese Medicine 2006;0(07):-
Objective To study the effect of Fengbei Huayu capsule on FasL gene expression and T cell apoptosis of type 2 diabetic rats, and to compare the pathological lesions of kidney and retina after treatment of traditional medicine. Methods To make the model of type 2 diabetic rats and determine the indexes of FasL gene expression and T cell apoptosis rate by RT-PCR, DNA gel electrophoresis methods. Results Compared the FasL gene expression and T cell apoptosis rate, TCM treatment group was significantly lower (P 0.05). Comparison of FasL gene express, TCM treatment group was significantly lower (P
3.Inhibitory Effects of Oridonin Combined with Gemcitabine on Pancreatic Cancer SW1990 Cells
Liming ZHOU ; Heqi BU ; Dianlei LIU ; Haimin JIN ; Mengtao ZHOU
Tianjin Medical Journal 2014;(9):859-862
Objective To investigate the inhibitory effects of oridonin combined with gemcitabine on pancreatic cancer SW1990 cells in vitro, and the potential mechanisms thereof. Methods The pancreatic cancer SW1990 cells were treated with vehicle alone and various concentrations (10,20,40,80 and160μmol/L) of oridonin, followed by 24, 48 and 72 h cell culture. Effects of oridonin on cell proliferation were determined by using a CCK-8 kit. SW1990 cells were treated with oridonin (40μmol/L) and gemcitabine (20μmol/L) alone or together for 48 h, and the untreated cells were used as the con-trol. The cell survival rate was detected by CCK-8 assay. Apoptosis induction was assessed by using Annexin V-FITC kit. Semi-quantitative RT-PCR was used to examine the changes of NF-κB mRNA and XIAP mRNA expressions. Results Oridonin inhibited the growth of pancreatic cancer SW1990 cells in a dose-and time-dependent manner. Compared with the other groups, the cell survival rate was significantly lower in the combination group (P<0.05). Oridonin combined with gemcitabine induced a higher percentage of apoptosis in pancreatic cancer cells than that of oridonin or gemcitabine alone (P<0.05). Moreover, the expressions of NF-κB and XIAP mRNA in pancreatic carcinoma cells were obviously down-regu-lated in combination group (P<0.05). Conclusion Oridonin can enhance the antitumor effect of gemcitabine on pancreatic cancer in vitro, which may be related to through the down-regulation of NF-κB and its downstream of XIAP, and then induc-ing cell apoptosis in pancreatic cancer.
4.Minimally invasive surgery in patients with middle-upper advanced gastric cancer
Haimin JIN ; Hai HUANG ; Xiaowen LI ; Ye LI
China Journal of Endoscopy 2017;23(6):71-76
Objective To investigate the effect of minimally invasive surgery in patients with midge-upper advanced gastric cancer (AGC). Methods 167 patients with middle-upper AGC underwent total gastrectomy+D2 lymph node dissection from January 2009 to December 2013 were enrolled in the study and divided into laparoscopic assisted total gastrectomy (LATG) group (n = 57) and open total gastrectomy (OTG) group (n = 110). Baseline data, operative, postoperative data and follow-up result were compared between the two groups. Results There were no significant differences in baseline data between the two groups (P > 0.05); The intraoperative blood loss and incision length in LATG group were significantly lower than that in OTG group (P < 0.05). There were no significant differences in operation time, ratio of intraoperative blood transfusion, distance between the upper margin and the tumor, the number of lymph node dissection between two groups (P > 0.05); Postoperative first aerofluxus time, ecovery liquid diet time, postoperative hospitalization days and VAS score of pain in 3 d after operation in LATG group were significantly lower than that in OTG group (P < 0.05). There was no significant differences in incidences of postoperative complication between two groups (P > 0.05); There was no patient dying within 30 d after surgery.The median follow-up time was 38.2 months (1~58 months). Postoperative 1, 3 year overall survival rates in LATG group and OTG group were 87.7% and 83.6%, 71.9% and 64.5%, and there were no significant differences between the two groups (P > 0.05). Conclusion For patients with middle-upper AGC, LATG+D2 lymph node dissection has lots of advantages including less intraoperative blood loss, shorter incision, faster postoperative recovery, shorter hospital stay and so on, which is safe and effective, and their short-and long-term results are satisfactory.
5.Clinical efficacy of different doses of alteplase in the treatment of acute cerebral infarction in older adult patients
Caidan LIN ; Xu ZHANG ; Xinlei MAO ; Yaxi ZHANG ; Haimin JIN
Chinese Journal of Primary Medicine and Pharmacy 2022;29(11):1664-1669
Objective:To investigate the clinical efficacy and safety of intravenous thrombolysis with different doses of alteplase in the treatment of acute cerebral infarction in older adult patients.Methods:A total of 65 older adult patients with acute cerebral infarction (onset within 4.5 hours, age ≥ 75 years) who underwent intravenous thrombolysis in Wenzhou Central Hospital from February 2021 to February 2022 were included in this study. They were randomly assigned to undergo intravenous thrombolysis with either low dose alteplase (0.6 mg/kg, low dose group, n = 32) or standard dose alteplase (0.9 mg/kg, standard dose group, n = 33). The National Institutes of Health Neurological Stroke Scale score before and 24 and 48 hours after treatment, modified Rankin scale score before and 7, 14 and 90 days after treatment, serum C-reactive protein (CRP), neuron-specific enolase (NSE) and tumor necrosis factor-α (TNF-α) levels before and 24 hours after treatment, 24-hour incidence of intracranial hemorrhage, 24-hour incidence of symptomatic intracranial hemorrhage, and 90-day mortality were compared between the two groups. Results:Compared with before treatment, the National Institutes of Health Neurological Stroke Scale scores in each group were significantly decreased at 24 and 48 hours after treatment (low dose group, t24 h = 6.78, t48 h = 7.86; standard dose group: t24 h = 8.09, t48 h = 10.13, all P < 0.001). Compared with before treatment, the modified Rankin scale score in each group was significantly decreased at 7, 14 and 90 days after treatment (low-dose group: t7 d = 5.19, t14 d = 8.47, t90 d = 9.85; standard dose group: t7 d = 6.83, t14 d = 7.74, t90 d = 13.66, all P < 0.001). At 24 hours after treatment, serum levels of CRP, NSE, TNF-α in each group were significantly decreased (low-dose group: tCRP = 5.13 , tNSE = 4.22, tTNF-α = 34.29; standard dose group: tCRP = 4.87, tNSE = 5.53, tTNF-α = 31.98, all P < 0.001). At each time point after treatment, there were no significant differences in these indices between the two groups (all P > 0.05). The 24-hour incidence of intracranial hemorrhage in the low dose group was significantly lower than that in the standard dose group ( χ2 = 4.58, P = 0.032). There were no significant differences in incidence of symptomatic intracranial hemorrhage and 90-day mortality between the two groups (all P > 0.05). Conclusion:Intravenous thrombolysis with low dose alteplase (0.6 mg/kg) for the treatment of acute cerebral infarction in older adult patients exhibits equivalent clinical efficacy to that with standard dose alteplase (0.9 mg/kg), and the former is much safer than the latter.
6.Prognostic roles of telomerase reverse transcriptase promoter mutation and 1p/19q co-deletion in newly-diagnosed O6-methylguanine-DNA methyltransferase promoter un-methylated/isocitrate dehydrogenase wild-type glioblastoma multiform
Qiong LU ; Xiwei ZHANG ; Yang WANG ; Xiaofang SHENG ; Xueyong WU ; Xiaobai WEI ; Hongyuan GAO ; Xiaofeng YIN ; Fang XIE ; Yueming ZHU ; Zhonghua JIN ; Zhenghua ZHANG ; Haimin WEI ; Dan LI ; Renhua HUANG ; Xianglian WANG ; Feng XIAO
Chinese Journal of Neuromedicine 2019;18(9):896-903
Objective To explore the prognostic values of telomerase reverse transcriptase promoter (TERTp) mutation and 1p/19q co-deletion in newly-diagnosed O6-methylguanine-DNA methyltransferase (MGMT) promoter un-methylated/isocitrate dehydrogenase (IDH) wild-type glioblastoma multiform (GBM). Methods A total of 82 patients pathologically newly-diagnosed MGMT promoter un-methylated/IDH wild-type GBM, admitted to our hospitals from March 2016 to November 2018, were included in this study. TERTp mutations (TERTp wild-type and TERTp mutation [C228 mutation and C250 mutation]) in GBM specimens were detected by PCR sequencing, 1p/19q co-deletion in GBM specimens was detected by fluorescence in situ hybridization (FISH), and clinical data, adverse reactions and prognoses of patients with different molecular typing were compared. Results There were 33 patients in the TERTp wild type group with mean age of 48 years, and 49 patients in the TERTp mutation group with mean age of 59 years; the difference of age was significant (P<0.05); there were no statistical differences in gender distribution, Karnofsky performance status (KPS) scores, tumor sites and surgical resection degrees between the two groups (P>0.05). There were 8 patients with 1p/19q co-deletion and 74 patients without 1p/19q co-deletion; no significant differences in above clinical parameters were noted between the two groups. There were no statistically significant differences in the incidences of bone marrow suppression, digestive tract response and fatigue, disease progression rate, or survival rate between patients from TERTp wild type group and TERTp mutation group, and between patients with 1p/19q co-deletion and patients without 1p/19q co-deletion (P>0.05). No significant differences in above clinical parameters, disease progression rate, and survival rate were noted between patients with C228 mutation and C250 mutation (P>0.05). Conclusion TERTp typing and 1p/19q co-deletion status do not have prognostic value in newly-diagnosed MGMT un-methylated/IDH wild-type GBM patients; patients with TERTp mutations have older age than wild-type patients; patients with C250 mutation trend to have higher survival rate than those with C228 mutation.
7.Effect of sarcopenia on balance function in patients with Parkinson's disease
Yaxi ZHANG ; Caidan LIN ; Haimin JIN ; Xiangdong HUANG
China Modern Doctor 2024;62(2):29-32
Objective To investigate the effect of sarcopenia on balance function in patients with Parkinson's disease(PD).Methods Sixty patients with PD diagnosed by our hospital from January 2021 to June 2021 were selected as the study objects.All patients were divided into myopenia group and control group according to the diagnostic criteria established by the Asian Working Group for Sarcopenia(AWGS)in 2014.The UPDRS Ⅲ,Berg balance scale,timed-up-go test and activity balance confidence scale were compared between the two groups.Results The grip strength,walking speed and RASM of the myopenia group were lower than those of the control group(P<0.05);Compared with the control group,the number of falls,UPDRS Ⅲ,Berg score and TUG duration in the myopenia group were significantly increased(P<0.05).The total score of ABC,ABC-2,ABC-3,ABC-5,ABC-6,ABC-7,ABC-8,ABC-9,ABC-11,ABC-14,ABC-15,ABC-16 in myopenia group were poor,and the differences were statistically significant(P<0.05).Further analyzing the differences between sex genders,we found that female sarcopenia had lower scores on ABC-2,ABC-3,ABC-8,ABC-9,ABC-11,ABC-13,ABC-14,ABC-15,ABC-16,and total score indexes,with statistically significant differences.Conclusion Myopenia significantly affects the balance function of PD and increases the risk of falls.